Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Conditions:   Gastrin-Producing Neuroendocrine Tumor;   Malignant Pancreatic Gastrinoma;   Malignant Pancreatic Glucagonoma;   Malignant Pancreatic Insulinoma;   Malignant Pancreatic Somatostatinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Beta Cell Adenoma;   Pancreatic Delta Cell Adenoma;   Pancreatic G-Cell Adenoma;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Pancreatic Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Pancreatic Cancer;   Stage IV Pancreatic CancerInterventions:   Drug: Everolimus;   Drug: Octreotide Acetate;   Biological: BevacizumabSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified July 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials